Abbott Announces New Data on Heart Rhythm Disorder Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ABT?
Abbott announced new late-breaking data from four trials that demonstrate "strong" clinical outcomes within its pulsed field ablation, PFA, and conduction system pacing, CSP, portfolios to treat heart rhythm disorders. New six-month data from the FlexPulse IDE study provide early insights showing "positive" patient outcomes with Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, and confirms the strong safety and efficacy profile seen in the CE Mark study for treating complex AFib cases. The data for the 188-patient FlexPulse IDE study show: The majority of patients reported being free from documented arrhythmias. A high safety profile with no major safety events. The majority of patients were treated exclusively with PFA, demonstrating that this energy source alone was successful in treating complex cases. Physicians efficiently treated their patients - 93.9% did not require an additional ablation after the first round of therapy. Results from two late-breaking clinical trials evaluated Abbott's investigational leadless and traditional pacing/defibrillation CSP technologies designed to deliver left bundle branch pacing, an approach intended to more closely replicate the heart's natural electrical activation. Key findings included: A high safety profile with no lead-related major safety events reported. A high success rate meeting left bundle branch area pacing criteria which can be compared to results from previously reported trial. An 86% success rate was met using the more stringent LBBP or likely LBBP criteria. An average of fewer than one repositioning attempt per patient was also achieved. 100% defibrillation success, with the majority achieving first shock success at 20J. No patients required repositioning of the ICD lead to achieve effective defibrillation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 93.860
Low
136.00
Averages
148.11
High
169.00
Current: 93.860
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Analysis of Abbott Laboratories
- Stable Dividend Returns: Abbott Laboratories has paid dividends for 399 consecutive quarters since 1924 and has increased its payout for 54 years, currently offering a dividend yield of 2.8%, providing investors with stable cash flow amid economic fluctuations.
- Strong Financial Growth: In the first quarter, Abbott's revenue grew nearly 8% year-over-year, with earnings per share (EPS) increasing by 6%, partly due to the acquisition of Exact Sciences, which enhances its expertise in oncology diagnostics, showcasing the company's success in diversification.
- Reasonable Valuation Levels: Abbott's forward-looking price-to-earnings (P/E) ratio stands at 16.6, below its five-year average of 23.6, and its price-to-sales ratio is 3.5, lower than the average of 4.8, indicating that its stock is attractive in the current market environment.
- Diversified Business Driving Growth: Abbott's cancer diagnostics business, medical devices portfolio, and product pipeline progress are viewed by management as key growth drivers, ensuring that even if one division falters, others can support overall performance.
See More
Analysis of Abbott Laboratories Holdings
- Holding Changes Overview: As of March 31, 2026, 25 hedge funds held Abbott Laboratories (ABT), with 6 increasing their positions and 14 decreasing, indicating a divergence in market sentiment towards the stock.
- Share Count Growth: Between the reporting periods of December 31, 2025, and March 31, 2026, the aggregate shares held by funds increased from 52,811,680 to 55,496,224, reflecting a growth of approximately 5.08%, showcasing sustained confidence in the company.
- Funds Exiting Positions: Notably, funds such as Baxter Bros Inc., Carlton Hofferkamp & Jenks Wealth Management LLC, Seascape Capital Management, and Core Wealth Advisors LLC exited their common stock positions in ABT during this period, suggesting a cautious stance from some investors.
- Investor Behavior Analysis: While 13F filings only reveal long positions, analyzing the changes across multiple funds provides a more comprehensive understanding of market sentiment, prompting investors to consider potential opportunities in Abbott Laboratories.
See More
Abbott Receives FDA and CE Clearance for Ultreon 3.0 AI Imaging Platform
- Technological Innovation: Abbott's Ultreon 3.0 AI-powered coronary imaging platform has received FDA and CE clearance, marking a significant advancement in its application for minimally invasive heart procedures, which is expected to enhance real-time guidance for physicians.
- Market Reaction: Prior to this announcement, Abbott's shares closed at $92.80 on Monday, reflecting a 1.83% increase, indicating positive market expectations and heightened investor confidence in the new technology.
- Application Prospects: The platform employs optical coherence tomography (OCT) technology to provide real-time guidance during minimally invasive procedures, which is anticipated to significantly improve the success rates of treating blocked coronary arteries, thereby enhancing patient outcomes.
- Strategic Implications: By launching Ultreon 3.0, Abbott not only solidifies its leadership position in the cardiovascular medical device market but also potentially strengthens partnerships with healthcare institutions through improved quality of care.
See More
Abbott Launches Ultreon 3.0 Advanced Imaging System for PCI
- Technological Innovation: Abbott's Ultreon 3.0 system has received FDA and CE clearance, integrating high-resolution coronary imaging with AI-automated insights to enhance treatment outcomes for complex coronary diseases, significantly improving patient prognosis.
- Clinical Decision Support: The platform provides real-time planning guidance, assisting physicians in accurately selecting stent locations and sizes, which is expected to positively impact over 600,000 patients in the U.S. and 885,000 in Europe undergoing PCI annually.
- Rapid Imaging Capability: Ultreon 3.0 features a one-second OCT pullback function that delivers higher resolution imaging than intravascular ultrasound while minimizing contrast use for patients with kidney disease, addressing the needs of approximately 25% of coronary artery disease patients.
- Workflow Optimization: The system streamlines physicians' workflows by providing clear information on blockage location and shape, ensuring improved blood flow post-stent placement, thereby enhancing the efficiency and accuracy of clinical decision-making.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
Abbott Unveils New Data on Heart Rhythm Disorder Treatments
- Clinical Trial Results: Abbott's FlexPulse IDE study revealed six-month data for the TactiFlex Duo Ablation Catheter, showing positive outcomes in 188 patients with complex atrial fibrillation, indicating strong safety and efficacy that supports its potential for FDA approval in the U.S.
- Innovative Treatment Modes: The TactiFlex Duo offers both radiofrequency and pulsed field ablation energy modes, allowing physicians to tailor treatment based on individual patient conditions, thereby enhancing personalization and effectiveness in cardiac care and advancing treatment methodologies.
- New Implantable Devices: The ASCEND CSP IDE trial demonstrated high implantation success rates for the UltiSynq CSP ICD lead in the left bundle branch area, with three-month data meeting primary safety and effectiveness endpoints, suggesting a shift in traditional pacemaker applications towards more physiologic pacing.
- Posterior Wall Ablation Data: Six-month data from the Volt PFA System indicate effective reduction in atrial fibrillation recurrence rates when treating the heart's posterior wall, further solidifying Abbott's innovative position in the cardiovascular field and driving the development of its comprehensive cardiovascular product portfolio.
See More
Investment Analysis of Abbott Laboratories
- Stable Dividend Returns: Abbott Laboratories has paid dividends for 399 consecutive quarters since 1924 and has increased its payout for 54 years, currently offering a dividend yield of 2.8%, providing investors with stable cash flow amid economic fluctuations.
- Strong Financial Growth: In the first quarter, Abbott's revenue grew nearly 8% year-over-year, with earnings per share (EPS) increasing by 6%, partly due to the acquisition of Exact Sciences, which enhances its expertise in oncology diagnostics, showcasing the company's success in diversification.
- Reasonable Valuation Levels: Abbott's forward-looking price-to-earnings (P/E) ratio stands at 16.6, below its five-year average of 23.6, and its price-to-sales ratio is 3.5, lower than the average of 4.8, indicating that its stock is attractive in the current market environment.
- Diversified Business Driving Growth: Abbott's cancer diagnostics business, medical devices portfolio, and product pipeline progress are viewed by management as key growth drivers, ensuring that even if one division falters, others can support overall performance.
See More
Analysis of Abbott Laboratories Holdings
- Holding Changes Overview: As of March 31, 2026, 25 hedge funds held Abbott Laboratories (ABT), with 6 increasing their positions and 14 decreasing, indicating a divergence in market sentiment towards the stock.
- Share Count Growth: Between the reporting periods of December 31, 2025, and March 31, 2026, the aggregate shares held by funds increased from 52,811,680 to 55,496,224, reflecting a growth of approximately 5.08%, showcasing sustained confidence in the company.
- Funds Exiting Positions: Notably, funds such as Baxter Bros Inc., Carlton Hofferkamp & Jenks Wealth Management LLC, Seascape Capital Management, and Core Wealth Advisors LLC exited their common stock positions in ABT during this period, suggesting a cautious stance from some investors.
- Investor Behavior Analysis: While 13F filings only reveal long positions, analyzing the changes across multiple funds provides a more comprehensive understanding of market sentiment, prompting investors to consider potential opportunities in Abbott Laboratories.
See More
Abbott Receives FDA and CE Clearance for Ultreon 3.0 AI Imaging Platform
- Technological Innovation: Abbott's Ultreon 3.0 AI-powered coronary imaging platform has received FDA and CE clearance, marking a significant advancement in its application for minimally invasive heart procedures, which is expected to enhance real-time guidance for physicians.
- Market Reaction: Prior to this announcement, Abbott's shares closed at $92.80 on Monday, reflecting a 1.83% increase, indicating positive market expectations and heightened investor confidence in the new technology.
- Application Prospects: The platform employs optical coherence tomography (OCT) technology to provide real-time guidance during minimally invasive procedures, which is anticipated to significantly improve the success rates of treating blocked coronary arteries, thereby enhancing patient outcomes.
- Strategic Implications: By launching Ultreon 3.0, Abbott not only solidifies its leadership position in the cardiovascular medical device market but also potentially strengthens partnerships with healthcare institutions through improved quality of care.
See More
Abbott Launches Ultreon 3.0 Advanced Imaging System for PCI
- Technological Innovation: Abbott's Ultreon 3.0 system has received FDA and CE clearance, integrating high-resolution coronary imaging with AI-automated insights to enhance treatment outcomes for complex coronary diseases, significantly improving patient prognosis.
- Clinical Decision Support: The platform provides real-time planning guidance, assisting physicians in accurately selecting stent locations and sizes, which is expected to positively impact over 600,000 patients in the U.S. and 885,000 in Europe undergoing PCI annually.
- Rapid Imaging Capability: Ultreon 3.0 features a one-second OCT pullback function that delivers higher resolution imaging than intravascular ultrasound while minimizing contrast use for patients with kidney disease, addressing the needs of approximately 25% of coronary artery disease patients.
- Workflow Optimization: The system streamlines physicians' workflows by providing clear information on blockage location and shape, ensuring improved blood flow post-stent placement, thereby enhancing the efficiency and accuracy of clinical decision-making.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
Abbott Unveils New Data on Heart Rhythm Disorder Treatments
- Clinical Trial Results: Abbott's FlexPulse IDE study revealed six-month data for the TactiFlex Duo Ablation Catheter, showing positive outcomes in 188 patients with complex atrial fibrillation, indicating strong safety and efficacy that supports its potential for FDA approval in the U.S.
- Innovative Treatment Modes: The TactiFlex Duo offers both radiofrequency and pulsed field ablation energy modes, allowing physicians to tailor treatment based on individual patient conditions, thereby enhancing personalization and effectiveness in cardiac care and advancing treatment methodologies.
- New Implantable Devices: The ASCEND CSP IDE trial demonstrated high implantation success rates for the UltiSynq CSP ICD lead in the left bundle branch area, with three-month data meeting primary safety and effectiveness endpoints, suggesting a shift in traditional pacemaker applications towards more physiologic pacing.
- Posterior Wall Ablation Data: Six-month data from the Volt PFA System indicate effective reduction in atrial fibrillation recurrence rates when treating the heart's posterior wall, further solidifying Abbott's innovative position in the cardiovascular field and driving the development of its comprehensive cardiovascular product portfolio.
See More
